The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 17, 2007
Filed:
Dec. 31, 2002
John A. Todd, Cambridge, GB;
John W. Hess, Lansdale, PA (US);
Charles T. Caskey, Houston, TX (US);
Roger D Cox, Oxon, GB;
David Gerhold, Lansdale, PA (US);
Holly Hammond, Telford, PA (US);
Patricia Hey, Lansdale, PA (US);
Yoshihiko Kawaguchi, Osaka, JP;
Tony R. Merriman, Dunedin, NZ;
Michael L. Metzker, Ft. Washington, PA (US);
Yusuke Nakagawa, Osaka, JP;
Michael S. Phillips, Lansdale, PA (US);
Rebecca C. J. Twells, Cambridge, GB;
John A. Todd, Cambridge, GB;
John W. Hess, Lansdale, PA (US);
Charles T. Caskey, Houston, TX (US);
Roger D Cox, Oxon, GB;
David Gerhold, Lansdale, PA (US);
Holly Hammond, Telford, PA (US);
Patricia Hey, Lansdale, PA (US);
Yoshihiko Kawaguchi, Osaka, JP;
Tony R. Merriman, Dunedin, NZ;
Michael L. Metzker, Ft. Washington, PA (US);
Yusuke Nakagawa, Osaka, JP;
Michael S. Phillips, Lansdale, PA (US);
Rebecca C. J. Twells, Cambridge, GB;
Merck & Co., Inc., Rahway, NJ (US);
Abstract
A novel receptor, 'LDL-receptor-related protein-5' ('LRP-5'), is provided, along with encoding nucleic acid. The gene is associated with type 1 diabetes (insulin dependent diabetes mellitus), and experimental evidence provides indication that it is the IDDM susceptibility gene IDDM4. In various aspects the invention provides nucleic acid, including coding sequences, oligonucleotide primers and probes, polypeptides, pharmaceutical compositions, methods of diagnosis or prognosis, and other methods relating to and based on the gene, including methods of treatment of diseases in which the gene may be implicated, including autoimmune diseases, such as glomerulonephritis, diseases and disorders involving disruption of endocytosis and/or antigen presentation, diseases and disorders involving cytokine clearance and/or inflammation, viral infection, elevation of free fatty acids or hypercholesterolemia, osteoporosis, Alzheimer's disease, and diabetes.